# US 2016/0256542 A1 · Use of a Lipopeptide or Lipoprotein as an Adjuvant in Therapeutic or Prophylactic Vaccinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256542 A1
- Document ID: US20160256542A1
- Status: Published application
- Kind: A1
- Application number: 13/848,936
- Filed: 2013-03-22
- Published: 2016-09-08
- Earliest claimed: 2002-04-04
- Assignees: Helmholtz-Zentrum fuer Infektionsforschung GmbH
- Inventors: Carlos Alberto Guzman; Peter Muhlradt
- Web page: https://patentgrep.com/patent/US20160256542A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61K 2039/541: {Mucosal route}
- A61K 2039/55516: {Proteins; Peptides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bis-palmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method of vaccinating an animal or human in need thereof, comprising the steps of:
providing said animal or human, via mucous membranes of said animal or human, with an antigen; and
providing said animal or human, via mucous membranes of said animal or human, with an adjuvant in the form of a lipopeptide or lipoprotein of the structure (I)
where
R1 and R2, which may be identical or different, are C7-25-alkyl, C7-25-alkenyl or C7-25-alkynyl,
X is S, O or CH2,
R3 and R4 are independently of one another H or methyl and
Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,
and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Ingold-Prelog rule, when X is S (sulfur).

### Claim 13 (depends on 12)

The method of claim 12, wherein the amino acid sequence Y is selected from
a)
(SEQ ID NO: 1)
GQTNT
b)
(SEQ ID NO: 2)
SKKKK
c)
(SEQ ID NO: 3)
GNNDESNISFKEK
and
d)
(SEQ ID NO: 4)
GQTDNNSSQSAAPGSGTTNT..

### Claim 14 (depends on 12)

The method of claim 12, wherein the lipoprotein or lipopeptide of structure (1) Is an S-[2,3-bispalmitoyloxy(2R)propyl]cysteinyl-peptide, where the peptide is a physiologically tolerated amino acid sequence which consists of 12 to 25 amino acid residues and is preferably not immunogenic in the species used.

### Claim 15 (depends on 12)

The method of claim 12, wherein the adjuvant is present in a preparation with the antigen, and wherein said providing steps are performed simultaneously by an administration route selected from the group consisting of intranasal administration, intra-NALT administration, aerosolized oral administration, intrarectal administration, conjunctival administration, intravaginal administration, intraurethral administration, and administration into the milk ducts of the female breast.

### Claim 16 (depends on 12)

The method of claim 12, wherein the adjuvant is present in a kit for coadministration with the antigen, and wherein each of said providing steps are performed by an administration route into the milk ducts of the female breast selected from the group consisting of intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal and intraurethral.

### Claim 17 (depends on 12)

The method of claim 12, wherein said providing an animal or human with an adjuvant step simultaneously provides at least one further adjuvant or antigen.

### Claim 18 (depends on 12)

The method of claim 12, wherein the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

### Claim 19 (depends on 12)

The method of claim 12, further comprising the step of providing, together with the lipopeptilde or lipoprotein, one or more anti-inflammatory, antiangiogenic, cytotoxic or immunomodulatory substances, ligands or antibodies.

### Claim 20 (depends on 12)

The method of claim 12, further comprising the step of providing the animal or human with further additives and excipients.

### Claim 21 (depends on 12)

The method of claim 12, wherein the antigen is present in the form of peptides, proteins, DNA, polysaccharides, glycolipids or glucoproteins.
